Hair Loss in Men: The Finasteride + Minoxidil Stack, Explained

What male pattern hair loss is

Androgenetic alopecia is the most common form of hair loss in men. It is genetic, slow, and driven by the conversion of testosterone to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT binds to hair follicles in the scalp and gradually shrinks them. Over a decade or two, the affected follicles produce thinner and thinner hairs until they stop producing at all.

Two interventions stop the process: blocking DHT at the follicle (finasteride or dutasteride) and improving follicular blood supply (minoxidil). Everything else. Biotin, peptides, lasers, scalp serums, is either marginal or untested.

Finasteride

Finasteride is a 5-alpha reductase type II inhibitor. At 1 mg orally per day, it lowers scalp DHT by roughly 60%. In the 5-year Propecia trial, 99.4% of men on finasteride either kept their hair or grew more. About two-thirds saw visible regrowth.

It works on the entire scalp, but it is most effective on the crown and mid-scalp. Hairline recession is harder to reverse than to prevent, which is why starting earlier matters more than starting bigger.

Side effects: the honest version

Roughly 1–2% of men in clinical trials reported sexual side effects: decreased libido, ED, reduced ejaculate volume. In the placebo arms, similar rates were reported, suggesting the effect is partially expectation-driven. Real cases exist; they are mostly reversible on stopping.

Some men report mood changes. A subset reports post-finasteride syndrome, a contested but real-to-the-people-it-affects condition. The honest stance: most men do well, a minority do not, and the practitioner asks at every check-in.

Minoxidil

Minoxidil was originally a blood pressure drug; the hair growth side effect became the indication. It is available topically (2% or 5% solution or foam) and orally as low-dose minoxidil (typically 2.5–5 mg).

Oral minoxidil has become the practical choice for many men because compliance is dramatically better. Side effects (mild fluid retention, palpitations at higher doses, body hair growth) are predictable and dose-dependent. Selvara prescribes after a practitioner reads the intake.

Dutasteride: the bigger gun

Dutasteride inhibits both type I and type II 5-alpha reductase. It reduces scalp DHT by roughly 90% versus finasteride's 60%. In direct trials, dutasteride produces more regrowth than finasteride.

The trade-off is a longer half-life (weeks versus hours), which means side effects, when they occur, take longer to resolve. It is usually a second-line option after finasteride or a first-line for men with aggressive loss.

Timelines: what to actually expect

Months 0–3: nothing visible. Some men shed slightly more. This is the older, weaker hairs cycling out before the new growth starts.

Months 3–6: shedding stabilizes. Texture improves first. Photos start to show density changes.

Months 6–12: most of the regrowth happens here. The first real before-and-after.

Year 1+: maintenance. The job is to keep what was won. Stopping the medication starts the loss again within 6–12 months.

What Selvara prescribes

Finasteride 1 mg orally per day, $59/month. Compounded at state-licensed pharmacies. Reviewed by a licensed practitioner. Refills automatic, adjustable in chat.

Frequently asked questions

Will finasteride affect my testosterone?

Total testosterone often rises slightly on finasteride because less of it is converted to DHT. DHT itself drops by about 60%.

How long until I see results?

Most men see visible changes at 6 months. Maximum results at 12–18 months.

If I stop, do I lose what I grew?

Yes. The drug stops the underlying process; it does not cure it. Stopping restarts the loss within 6–12 months.

Can I do finasteride alone or do I need minoxidil too?

Finasteride alone works for most men. Adding minoxidil produces more regrowth, especially on the crown.

1. Kaufman KD et al., "Long-term (5-year) multinational experience with finasteride 1 mg in men with androgenetic alopecia," Eur J Dermatol, 2002.
2. Olsen EA et al., "The importance of dual 5α-reductase inhibition," J Am Acad Dermatol, 2006.